News Release
 

September 16, 2011

CONTACT:Karen Kreeger
215-349-5658
Karen.Kreeger@uphs.upenn.edu

Penn Medicine - University of Pennsylvania School of Medicine and University of Pennsylvania Health System


This release is available online at
http://www.uphs.upenn.edu/news/News_Releases/2011/09/penning-pcf-grant/

Penn Pharmacologist Receives Grant from Prostate Cancer Foundation to Find New Ways to Fight Drug Resistant Tumors

PHILADELPHIA —Trevor Penning, PhD, professor of Pharmacology at the Perelman School of Medicine at the University of Pennsylvania, and colleagues have received a 2011 Prostate Cancer Foundation Challenge Award. This is a multi-investigator grant awarded to Penn, Harvard University, University of Washington-Fred Hutchinson Cancer Center, and Beth Israel Deaconess Hospital to find new treatments for patients with advanced prostate cancer. The grant totals $500,000 per year for up to three years for all investigators.

Penning's role in the Prostate Cancer Foundation (PCF) award is two-fold. The first is to develop sophisticated assays to detect trace levels of male hormones called androgens in castrate-resistant prostate cancer (CRPC).  CRPC is uniformly fatal and emerges because the tumor finds a way to make its own androgens.  The new methods will allow the researchers to determine the source and fate of androgens within the disease, as well as mechanisms of drug resistance so that personalized therapies can be developed.

The second role is to develop inhibitors of a highly expressed protein (type 5 17beta-hydroxysteroid dehydrogenase) thought to be involved in the synthesis of androgens in CRPC within the prostate. Like other forms of prostate cancer, CRPC is androgen-dependent, but the tumor becomes aggressive by finding a way to by-pass castration by synthesizing its own hormones for growth.

“New therapies for CRPC target androgen synthesis, however, in many instances drug resistance can occur,” notes Penning. “The problem is that all patients are treated the same irrespective of how the tumor adapts to make its own androgens.” The research proposed will lead to tailored therapies for CRPC.

Abiraterone acetate (Zytiga), recently approved by the FDA for treatment for metastatic prostate cancer and soon to be approved within the European Union, is a new drug currently used after chemotherapy. As with previously approved treatments, patients invariably become resistant to abiraterone by mechanisms largely unknown. Overall, the team of researchers will investigate treatment-resistance mechanisms in abiraterone-resistant patients. Based on these findings, the team will design new androgen receptor pathway-targeted medications that should result in durable cancer remission.

"PCF Challenge Awards support transformational prostate cancer research teams to accelerate progress towards the reduction of death and suffering due to recurrent or advanced prostate cancer," comments Howard R. Soule, PhD, PCF chief science officer. "This multi-institutional research program will significantly advance our knowledge of why some men become resistant to treatment with abiraterone and identify new targets and treatments for them."

The PCF Challenge Awards will support a total of 10 scientific projects nationwide.

Co-investigators are Peter Nelson, MD; Glenn Bubley, MD; Toni Choueiri, MD; Phillip Kantoff, MD; Christopher Sweeney, MD; Mary-Ellen Taplin, MD; Steven Plymate, MD; Robert B. Montgomery, MD; Robert Vessella, PhD; Lawrence True, MD; Alvin Matsumoto, MD; Elahe Mostaghel, MD, PhD

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.